Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 5/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4234355 | 0.94 | TAS1R3 (0.57) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4227920 | 0.88 | TAS1R3 (0.47) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4229012 | 0.85 | PKM (0.50) | TAS1R3TAS1R1PKMPOLBMEN1 | |
| SCHEMBL4236756 | 0.84 | MEN1 (0.43) | TAS1R3TAS1R1KDRPDGFRAKIT | |
| SCHEMBL4226776 | 0.84 | PKM (0.54) | TAS1R3TAS1R1PKMKDRPOLB | |
| SCHEMBL4237834 | 0.84 | TAS1R3 (0.55) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4237265 | 0.83 | TAS1R3 (0.52) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4232323 | 0.82 | TAS1R3 (0.53) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4233572 | 0.82 | TAS1R3 (0.55) | TAS1R3TAS1R1PKMKDRPDGFRA | |
| SCHEMBL4232752 | 0.82 | TAS1R3 (0.55) | TAS1R3TAS1R1PKMKDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TAS1R3 1436/4885TAS1R1 1073/4885PKM 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.